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Abstract 
Purpose: To prepare and characterize a water-in-oil nanoemulsion of 5-fluorouracil (5FU) for enhanced 
skin penetration.  
Methods: Nanoemulsions of 5FU were prepared using Capyrol (propylene glycol monocaprylate). 
Transcutol (highly purified diethylene glycol monoethyl ether) and polyethylene glycol (PEG) 400 as oil, 
surfactant and co-surfactant, respectively. The optimized formulations were subjected to heating - 
cooling cycling, centrifugation and freeze - thaw cycling to assess their stability. Particle size distribution 
and zeta potential of the nanoemulsions were evaluated. Furthermore, in vitro and in vivo skin 
permeation studies were carried out on the formulations in a rat model. Skin irritation studies were also 
performed on rats to assess the irritation potential of the formulations.  The 1 % w/v of Carbopol 934 gel 
loaded with 1 % 5FU was used as control (FU gel).  
Results: The results showed that the mean droplet size of the nanoemulsions was ~100 nm with a zeta 
potential of ± 15. Significant increase in permeability was also observed for the nanoemulsion 
formulations compared with control. The steady-state flux (Jss), enhancement ratio and permeability 
coefficient (Kp) for optimized nanoemulsion formulation were significantly (p < 0.05) higher than those of 
the conventional gel (control). Both in vitro and in vivo skin retention results indicate higher drug release 
from the nanoemulsion (292.45 µg/cm2) than for control (121.42 µg/cm2). Mean irritation index for the 
nanoemulsion was significantly lower than for control.  
Conclusion: The results suggest that a water-in-oil nanoemulsion is safe and can potentially be used to 
promote skin penetration of 5FU following topical application on the skin for the treatment of some skin 
diseases.  
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5-Fluorouracil (5FU) is an antineoplastic agent 
used for the treatment of skin diseases such as 
psoriasis, cutaneous premalignant, malignant 
lesions and basal-cell carcinoma [1]. However, in 
each instances less than optimal delivery of 5-FU 
using conventional preparations has 
necessitated the use of more invasive measures 
to obtain therapeutic outcomes. The ideal drug 
delivery for most skin diseases is for the drug to 
be able to penetrate deeper skin layers. As such 
the drug delivery strategy should be made to 
localize high drug concentrations inside the 
epidermis and dermis layers for effective therapy 
[2]. There has been an increased interest during 
recent years in the use of topical vehicle systems 
using permeation enhancers [3], but use of these 
chemical enhancers may be harmful, especially 
in chronic application. Therefore, topical vehicle 
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systems could be made safer without chemical 
enhancers to facilitate drug permeation through 
the skin. One of the most promising formulation 
for enhancement of skin permeation of drugs is 
nanoemulsion [4]. 
 
Nanoemulsions are thermodynamically stable 
transparent (translucent) dispersions of oil and 
water stabilized by an interfacial film made by 
surfactant and co-surfactant molecules having a 
droplet size of less than 100 nm. The 
antiproliferative 5-FU has been extensively used 
as a topical chemotherapy for most skin diseases 
like cutaneous premalignant, malignant lesions 
and skin cancer (Basal-cell carcinoma [5]. 
Therefore, an improved 5FU nanoemulsion 
formulation with a high degree of permeation 
could be useful in the treatment various skin 
diseases. The present study describes the 
potential of nanoemulsion systems for topical 
delivery of 5FU that achieve the goal of 
increased skin permeation without the use of 






5-Fluorouracil was purchased from Spectrum 
Chemicals, Malaysia. Capryol 90, Labrasol, 
Transcutol HP, Capyrol PGMC, Lauroglycol- 90, 
Plurol oleique CC497, Maisine 35-1, Solutol were 
gifted by Gattefosse, France. Span 80 Tween 60 
and Tween 80 were purchased from R&M 
Marketing, United States of America (USA).  
PEG 300 and PEG 400 were acquired from 
Aldrich, Germany.  Ethanol and Span 80 were 
obtained from Fisher Chemicals and Fluka, USA 
respectively. Other chemicals used were of 
analytical reagent grade.  All chemicals were 
used as received. 
 
Solubility studies  
 
The solubility of 5FU in various oils was 
determined by adding excess amount of the drug 
in 2 mL of selected oils, surfactants and co-
surfactants in 5mL vials, which were mixed 
thoroughly using a vortex mixer [6]. The vials 
placed in water bath - shaker for 24 h and the 
temperature was kept at 25 °C.  After that, the 
mixtures were spun using a centrifuge (Bench 
Top Refrigerated, Eppendorf) at 3000 rpm for 15 
min. The supernatants were sampled and 
quantified using a HPLC method. A Shimadzu 
HPLC system (Shimadzu, Japan) with two LC-
10AT VP pumps with UV detector set at 260 nm 
and a RP C-18 column (150 mm x 4.6 mm I.D.; 
particle size 5 was used to quantify the 5FU 
content in solution.   
 
Construction of pseudoternary phase 
diagrams 
 
The ternary the pseudo-ternary phase diagram 
has been constructed based solubility of drug in 
each solvent (oil, surfactant and co-surfactant) 
[7]. The surfactant and co-surfactant were mixed 
in different ratios (1:1, 2:1, and 3:1). Phase 
diagrams were constructed for each ratio of 
mixture of surfactant - co-surfactant (Smix) and 
oils. For every phase diagram, the proportion of 
oil and Smix varies in different volume ratio from 
0:10 to 10:0. The percentage of the aqueous 
phase was determined using an aqueous titration 
method [8]. Slow titration of distilled water was 
added (5 % addition at a time) into the Smix - oil 
mixture and the observation of the transition from 
clear to turbid point was recorded. A calculation 
was made to determine the percentage of water, 
oil and Smix present at the point of turbidity. With 
the obtained individual percentage, a pseudo-
ternary phase diagram was constructed with the 
clear-solution region marked and defined as the 
best emulsification region.  
 
Preparation of nanoemulsion  
 
From each phase diagram constructed, different 
points were selected from nanoemulsion region 
for incorporation surfactant, co-surfactant and oil. 
1 % (w/w) of FU was dissolved in aqueous phase 
(distilled water) of all selected nanoemulsion 
formulation. Then, a selected quantity of Smix 
(mixture of surfactant and co-surfactant) was 
added into the aqueous solution of the drug. The 
mixtures were stirred for 2 min and sonicated 
until the drug dissolved completely. The oil phase 
(Capyrol PGMC) was added slowly with 
continuous stirring. The resulting mixtures were 
then passed through a high pressure 
homogenizer (Avestin Emulsifex C3) for 5 cycles.   
 
Thermodynamic stability testing 
 
The formulations were subjected to heating-
cooling, centrifugation and freeze-thaw stability 
testing programme, where the physical 
appearances of the formulations were observed 
at each testing period. In the heating-cooling 
programme, all six formulations were heated at 
45 °C and then cooled at 4 °C, with a duration of 
24 h at each temperature, for 2 cycles. Then, 
formulations which passed the heating-cooling 
cycles were subjected to centrifugation at 3500 
rpm for 15 min. Finally, only formulations which 
passed the previous two steps were stored at 
alternating temperature of -21 and 25 °C, with a 
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duration of 24 h at each temperature, for 2 
cycles. 
 
In vitro skin permeation studies  
 
Skin of 8-9 weeks old Swiss albino mice 
weighing 25 to 30 g was mounted in a Franz 
diffusion cell. The skin was washed with normal 
saline then dried between two filter papers. The 
skin was then carefully checked through a 
magnifying glass to ensure that samples were 
free from any surface irregularities such as tiny 
holes or cervices in the portion. 2 cm2 of the 
excised skin samples were clamped between the 
donor and receptor chamber of a Franz diffusion 
cell with the stratum corneum facing the donor 
chamber. Then, 2 ml of prepared nanoemulsion 
formulations were administered into the donor 
chamber. The receptor chamber was filled with 
15 ml of phosphate buffer solution (PBS) pH 7.4.  
The receptor medium was maintained at 37 ± 0.5 
oC and stirred at 500 rpm throughout the 
experiment. 0.5 ml of sample was collected from 
the receptor medium of each cell every hour for 8 
hours and then immediately replaced by the 
same amount of preheated PBS. The collected 
samples were filtered through a 0.45 μm pore 
size cellulose membrane filter and analyzed 
using a HPLC method as described above [9].  
All animal protocols were approved by the 
Animal Ethics Committee of International Medical 
University, Malaysia (approval ref. no 
IAEC/BP/2012/0087). The animal experiment 
was performed in accordance with Directive 
2010/63/EU on the handling of animals used for 
scientific purposes [10]. 
 
Permeation data analysis 
 
The cumulative amount of drug permeated 
through the skin (µg/cm2) was plotted against 
time in hours for each formulation. The drug flux 
(permeation rate) at steady-state (Jss) and 
permeability coefficient (KP) were calculated 
from the slope of the linear portion of the graph 
using Eq 1 [11]. 
 
KP = JSS/C0 ……………………………… (1)  
where, Jss is the drug flux at steady state and C0 
is the initial drug concentration in the donor cell. 
Enhancement ratio (Er) was calculated by 
dividing the Jss of respective formulation with Jss 
of control formulation as in Eq 2. 
 
Er = JssF/JssC ……………………………. (2) 
 
where, JssF is the Jss of formulation and JssC is 
the Jss of control. 
 
The significance of results was checked 
statistically at p < 0.05 applying a one-way 
ANOVA test. Post hoc multiple comparisons 
were carried out using the least square 
difference test [12]. 
 
In vivo skin deposition studies 
 
8-9 weeks old male Swiss albino mice weighing 
20 to 25 g were used for this study. The animals 
were divided into 5 groups, with each group 
consisting of 5 animals. Prepared nanoemulsion 
FU2, placebo formulation (control), 5 % SLS and 
plain carbopol gel containing 1 % 5FU (plain gel) 
were applied to the dorsal surface (3 cm2) of 
each group of mice after removal of its hair by 
clipping. The mice were then put to death by 
cervical dislocation at the end of 1, 2, 4 and 8 
hours after dorsal application and the 
administered skins were stripped and adhering 
fats and debris were removed carefully. The skin 
was thoroughly washed with methanol and then 
dried. The drug content in the dermis skin layer 
was determined as described in the in vitro skin 
deposition study and drug content was analyzed 
by the HPLC method. 
 
Skin irritation studies 
 
Wistar albino rats (16 weeks) weighing 200 - 250 
g were used in this part of the study [12]. The 
animals were kept under standard laboratory 
conditions, with standard temperature of 25 °C ± 
1 °C and relative humidity of 60 %.  They had 
free access to a standard laboratory diet with 
water ad libitum. Prior to the application of 
formulations onto the animals, the hairs on the 
dorsal surface of the rats were removed by 
clipping. Five rats were assigned to each 
treatment groups: Group 1 received placebo 
formulation (negative control), Group 2 received 
sodium lauryl sulphate (SLS) solution (5 % w/v, 
positive control), Group 3 received prepared FU2 
nanoemulsion formulation and Group 4 received 
carbopol gel containing 1 % 5FU.  200 µl of 
these prepared samples were applied onto the 
dorsal surface of the rats daily for six days using 
the reported method [13].  The rats were 
observed and erythema scores ranging from 0 to 
4 were allocated depending upon the degree of 
erythema as follows, 0: No erythema 1: Slight 
erythema (barely perceptible light pink). 2: 
Moderate erythema (dark pink). 3: Moderate to 





Data are presented as mean ± standard (SD). 
The difference in results between batches 
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containing various portion of excipients was 
statistically analyzed using Student's t-test with 
the aid of SPSS 16.0 statistical software. 
Differences were considered statistically 






In order to select the suitable solvents for the 
preparation of nanoemulsions, the solubility of 
5FU various oil, co-surfactants and surfactants 
were determined and the results are shown in 
Figure1. The drugs that 5-FU has shown good 
solubility in are Trancutol HP, Capyrol PGMC 
and PEG 400 with a solubility of 94.62, 78.94 
and 93.12 mg/mL respectively. 
 
Construction of pseudoternary phase 
diagrams 
 
A phase diagram was constructed on the basis of 
the solubility of drug, oil, surfactants, co-
surfactants and aqueous phase. The aqueous 
titration was performed with addition of water (5 
% increment of up to 95 % [14]. As shown in 
Figure 2, the area of nanoemulsion region in the 
phase diagram appeared to have decreased 
minimally when the Smix ratio increases. The Smix 
1:1 shows a larger nanoemulsion region than 
that of 3:1. 
 
It was also noticeable that the Smix 1:1 ratio took 
up a greater amount of water and still remained 
as a clear mixture during aqueous titration. In 
Figure 2, the region A forms a clear emulsion 
while B & C formed more turbid and milky 
emulsions. 
 
Preparation of nanoemulsion  
 
The nanoemulsifying region incorporating 1 % 
W/V of 5FU in Smix 1:1 appeared to be larger (p < 
0.05) than that of the other Smix formulation ratios 
(1:2 and 1:3) in the presence of drug (Figure 
2(a)). Six points were randomly picked from the 
self-nanoemulsifying region from Smix 1:1 and 
each formulations composition are shown in 
Table 1. 
 
Droplet size  
 
The mean droplet size of 5-FU nanoemulsions 
was in the range of 80.24 -112.87 nm. The 
droplet size of nanoemulsion was increased with 
the increase in concentration of oil (Capyrol 
PGMC) as shown in Table 2. 
 




Figure 2: Pseudoternary phase diagrams of Capyrol PGMC, Transcutol and PEG 400 with 100 mg of 5FU. a) 
Smix 1:1; b) Smix 2:1  c) Smix 3:1 
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Components (%w/w) Smix ratio 































* Aqueous phase (water) containing 1 % w/v of 5FU 
 
The formulation containing 60 % (FU3) oil has 
the highest particle size (112.87 ± 1.78) and 
formulation containing 20 % water and 50 % oil 
has the lowest particle size  (80.24 ± 2.14) nm) 
as compared to other formulations.  The results 
from Table 2 show that all the formulations had 
droplets in the nanometer range with low values 




The results of stability testing for the 
nanoemulsion are shown in Table 3. All of the 
optimized formulations passed the 
thermodynamic stability testing (freeze thaw 
cycle) as none of them exhibited any sign of 
phase separation or drug precipitation at the end 
of the cycles. 
 
In vitro skin permeation  
 
The in vitro release profiles of 5FU from its 
various nanoemulsion formulations containing 1 
% w/v of 5FU (FU1, FU2, FU3, FU4) and plain 
carbopol gel containing 1 % of 5FU are 
presented in Figure 3.  The in vitro skin 
permeation was found to be highest for 
formulation FU1 and lowest for FU3 (Figure 3). 
The skin permeation profile of FU1 was 
significantly (p < 0.05) higher as compared to 
FU3. In vitro skin permeation parameters of 
prepared nanoemulsion formulations and control 
are shown in Table 4. 
 
It was observed that the permeation parameters 
cumulative amounts of drug permeated, steady-
state flux values, enhancement ratios and 
permeability coefficients in all nanoemulsion 
based formulation (FU1, FU2, FU3 and FU4) 
were found to be significantly (p < 0.05) higher 
than that of FU loaded  conventional gel at the 
end of  the 8h permeation study as shown in 
Table 4. The amount of drug permeated from its 
nanoemulsion formulation through the skin can 
be arranged in the following descending order: 
FU1>FU3>FU2>FU4, where the amounts of the 
drug penetrated after the 8h of study were 
196.36, 156.25, 136.25 and 112.21 µg/cm2, 
respectively. In contrast, in vitro skin permeation 
of conventional gel containing 1 % 5FU was 
observed to be significantly (p < 0.05) lower 
(60.12 µg/cm2) at the end of 8h. 
 
 
Table 2: Mean droplet size, polydispersity index and zeta potential (mV) of each formulation used in the study 
 
Formulation Mean droplet size 
(nm) 







82.28 ± 1.98 
93.54 ± 2.17 
112.87 ± 1.78 
98.45 ± 1.87 
97.51 ± 1.28 
80.24 ± 2.14 
0.328 ± 0.040 
0.228 ± 0.040 
0.310 ± 0.021 
0.211 ± 0.032 
0.397 ± 0.047 
0.258 ± 0.041 







Table 3: Mean droplet size, polydispersity index (PDI) and zeta potential (mV) of the optimized nanoemulsions 
after exposure to a freeze thaw cycle 
 







81.24 ± 2.27 
93.27 ± 2.19 
109.27± 2.14 
96.78 ± 2.78 
97.89 ± 2.47 
84.47 ± 2.12 
0.218 ± 0.030 
0.317 ± 0.031 
0.288 ± 0.028 
0.218 ± 0.031 
0.309 ± 0.044 
0.271 ± 0.056 
-13.45 ± 0.244 
-14.21 ± 0.141 
-15.25 ± 0.134 
-16.30 ± 0.289 
-10.71 ± 0.315 
-14.58  ± 0.282 
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Time (h)


































Figure 3: In vitro skin permeation of 5-FU from nanoemulsion through excised mice skin in a Franz diffusion cell 
at 37 ± 0.5 °C; mean ± SD (n = 3) 
 
     Table 4: In vitro permeation parameters of 5FU from nanoemulsions (mean ± SD, n = 3) 
 
















7.38  ± 1.57 
3.28 ± 0.87 
2.27 ± 0.48 
1.80 ± 0.29 
2.54 ± 0.81 
1.00 ± 0.19 
0.89 ± 0.18 
0.74 ± 0.17 
0.38 ± 0.19 
0.75 ± 0.21 
0.21 ± 0.02 
19.52 ± 1.87 
12.45 ± 1.24 
11.86 ± 1.45 
17.45 ± 1.69 
6.47 ± 1.27 
 
 In vivo skin deposition  
 
Based on the in vitro skin permeation results, the 
nanoemulsion formulation FU1 and the aqueous 
cream were selected for in vivo skin deposition 
studies.  The amount of drug retained on mice 
skin for different time intervals (1h, 2h, 4h and 
8h) are shown in Figure 4. It was observed that 
the there was no significant (p < 0.05) difference 
in skin deposition in FU2 at different time 
intervals and that the maximum amount of 
deposition (292.45 µg/cm2)  was reached at the 
end of 2 h at which point there was no further 
increase of drug deposition observed. 
 
 
Figure 4: Amount of 5-FU retained in rat skin at the end of 8 hours of in vivo deposition studies; (mean ± SD, n = 
3
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On the other hand, it was noticed that the 
amount of drug retained in 5FU loaded 
conventional gel was 121.42 µg/cm2 at the end of 
the 8 h study and this was attributed to a lower 
ability of the cream formulation to penetrate the 
skin layers. Finally, all the nanoemulsion based 
formulations (FU1, FU2, FU3 and FU4) showed 
good in vitro penetration, in vitro skin deposition, 
and in vivo skin deposition in mice skin. Out of all 
the formulations, FU1 showed the maximum in 
vitro penetration and in vivo skin deposition as 
compared to the other formulations (Figure 3 & 
4). 
 
Skin irritation  
 
The study was conducted to test the safety and 
skin irritation caused by formulations. The mean 
erythema scores upon application of optimized 
nanoemulsion FU1, 5 % W/V SLS solution 
control (placebo) and carbopol plain gel of 1 % 
5FU are shown in Figure 5. The SLS solution (5 
% W/V) was used as standard irritation in this 
study. Results indicate that erythema caused by 
SLS were much higher (4.1 level score) 




Figure 5: Mean irritation index of various 5-FU 
nanoemulsion and 5-FU conventaional cream; (mean 




The drug has shown the highest solubility in 
Transcutol HP and it has been chosen as the 
surfactant for this study. Similarly, PEG 400 and 
Capyrol PGMC were chosen as the oil and co-
surfactant, respectively, for this study. 
Furthermore, Transcutol HP reported to be very 
attractive as a penetration enhancer due to its 
non-toxicity and biocompatibility with the skin 
[14].  The right blend of oil and surfactants with 
the right value of hydrophilic lipophilic balance 
(HLB) leads to the formation of stable 
nanoemulsion formulations. In this study, HLB 
value of blend of oils and surfactants were found 
to be ~ 5.3 which is in the range for W/O type of 
emulsion. 
 
In Figure 2, diagram (a) has shown the largest 
emulsification area. This could be explained by 
the fact that a higher number of surfactants can 
be absorbed at the interface, thus stabilising the 
formation of nanoemulsions [15]. Hence, the ratio 
of 1:1 was selected for formulation development 
and 6 random points within this area was 
selected to be used for further studies. A 
pseudoternary phase diagram in the presence of 
1 % W/V 5-FU was also plotted with Smix 1:1 to 
determine the effect of drug on the phase 
diagram [16].  Smix 1:1 ratio showed no difference 
in the area of nanoemulsion whether with the 
presence or absence of 1 % 5FU. 
 
Determining the droplet size is of great 
importance in nanoemulsion formulations as 
small globule sized emulsion contributes to a 
greater interfacial area which can then provide 
better drug partitioning and absorption. However, 
there is no consensus in the literature on the 
exact size range of a nanoemulsion [16]. The 
polydispersity values of all formulations were 
very low which indicates uniformity of droplets 
within the formulation. The Zeta potential of the 
formulation was also measured in order to 
determine the interaction between colloidal 
particles, where large positive or negative values 
suggesting high inclination of emulsion repulsion 
and hence, stability [17]. 
 
The results from thermodynamic stability studies 
of the optimized preparation shows good stability 
against acceleratory stability condition. The 
average particle size and physical appearance of 
the formulation after the stability study at extreme 
conditions was observed and the results 
indicated that there were no significant changes 
in particle size or physical appearance (Table 5). 
 
Table 5: Physical appearance of nanoemulsion after 
exposure to a freeze thaw cycle 
 
Sample Observation  
(after first cycle & 
centrifugation) 
Observation  






















The significant difference in drug permeation 
between nanoemulsion formulations FU1 and 
FU3 was probably due to the mean size droplets 
[18], which were significantly smaller for FU than 
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for FU2 and FU3 and also due to the higher 
amount of penetration enhancer (Transcutol and 
Capyrol PGMC) used in the FU1 formulation 
which may work by interacting with the structural 
components of the stratum corneum to enhance 
drug penetration [19].  
 
It was observed that the in vitro skin permeation 
parameter values of 5FU gel preparation were 
much lower than that of the nanoemulsion shown 
in Figure 4. This could be due to the low flux and 
high viscosity of the formulation which can 
explain the lesser in ability for the aqueous 
solution to penetrate skin layers as compared to 
nanoemulsion formulations as shown in Figure 4. 
In this study, Transcutol was used as the 
surfactant in this study and this compound has 
been reported for its skin penetration-enhancing 
effect [18,19]. Capyrol PGMC was used as the oil 
in this study and this oil is known for its 
penetration-enhancing effect by altering the skin 
texture [20]. Moreover, the characteristics of 
nanoemulsions such as high drug concentration, 
the small droplet diameter and the reaction 
between the surfactants and skin stratum 
corneum could have been contributed to the 
permeation-enhancement of the prepared 
formulations.  
 
From the above in vivo and in vitro permeation 
data, it was found that all of the prepared 
nanoemulsions could improve the skin 
permeation of 5FU over the conventional gel that 
has the same drug concentration. This could be, 
as reported previously, the thermodynamic 
activity of formulations which can be described 
as viscosity is important to the permeation into 
skin. It is known that the viscosity of 
nanoemulsions is much lower than that of gel, so 
the mobility of drug in nanoemulsions is more 
facile. Furthermore, the nanoemulsions may 
affect the stratum corneum structure and reduce 
the diffusional barrier by acting as a permeation 
enhancer [20,21]. 
 
In the skin irritation study, the mean irritation 
score of FU1 was significantly lesser than that of 
the plain gel. The results clearly indicate that the 
optimized nanoemulsion formulation was well 
tolerated by rat skin and produced no irritation to 
skin. Based on this, it seems that the optimized 
nanoemulsion formulation may be safe used for 
topical drug delivery compared to conventional 




The penetration of 5FU into the skin and its 
retention within the skin is desirable for the 
treatment of many skin diseases, including skin 
cancer. Thus, the developed nanoemulsion 
formulation has great potential for topical delivery 
of 5FU for safe and more effective treatments of 
various skin diseases including skin cancer. 
However, further studies, such as extensive 
pharmacokinetic, histopathological and toxicity 
studies are required to fully develop these 
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